Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study

Table 2 Stepwise multiple logistic regression analysis of risk factors associated with invasive cryptococcosis due to fluconazole-non-susceptible C. neoformans^b

Factors	Comparison	OR (95 % CI)	p
Admission during 2011-2012	Yes vs. No	10.68 (2.87-39.74)	<0.001
Liver cirrhosis	Yes vs. No	0.17 (0.02-1.58)	0.12
Initial present with sepsis	Yes vs. No	1.86 (0.62-5.62)	0.27
Azole exposure^a	Yes vs. No	3.33 (0.73-15.25)	0.12

Azole exposure^a: patients received azole therapy (fluconazole, voriconazole, itraconazole, or ketoconazole) for more than 48 h within 3 months prior to the first episode of invasive cryptococcosis
OR odds ratio, CI confidence interval
^bStatistically significant variables in univariate analyses between these categories were entered into multivariate analysis using a logistic regression model. Statistical significance was set at a two-tailed p < 0.05

ISSN: 1471-2334